Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

NCT03740165 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1367

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Neoplasms

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Placebo for pembrolizumab
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Olaparib
DRUG: Placebo for olaparib
BIOLOGICAL: Bevacizumab
DRUG: Docetaxel

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]
[object Object]